drugset / Trial / NCT05172037
Novaferon in Non-hospitalized Adult Patients With Mild COVID-19
RandomizedParallel-groupDouble-blindTreatment
Summary
An Adaptive, Multicenter, Randomized, Double-blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Aerosolized JH509 vs. Placebo in Non-hospitalized Adult Patients with Mild COVID-19
Timeline
- Start
- 2021-10-28
- Primary completion
- 2022-03
- Completion
- 2022-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Novaferon | Protein / enzyme biologic | 20 ug | Inhaled |